Tuberculosis (TB) is an infectious bacterial disease that kills approximately 1.3 27 million people every year. Despite global efforts to reduce both the incidence 28 and mortality associated with TB, the emergence of drug resistant strains has 29 slowed any progress made towards combating the spread of this deadly 30 disease. The current TB drug regimen is inadequate, takes months to complete 31 and poses significant challenges when administering to patients suffering from 32 drug resistant TB. New treatments that are faster, simpler and more affordable 33 are urgently required. Arguably, a good strategy to discover new drugs is to 34 start with an old drug. Here, we have screened a library of 1200 FDA approved 35 drugs from the Prestwick Chemical library ® using a GFP microplate assay. 36 Drugs were screened against GFP expressing strains of Mycobacterium 37 smegmatis and Mycobacterium bovis BCG as surrogates for Mycobacterium 38 tuberculosis, the causative agent of TB in humans. We identified several 39 classes of drugs that displayed antimycobacterial activity against both M. 40 smegmatis and M. bovis BCG, however each organism also displayed some 41 selectivity towards certain drug classes. Variant analysis of whole genomes 42 sequenced for resistant mutants raised to florfenicol, vanoxerine and 43 pentamidine highlight new pathways that could be exploited in drug repurposing 44 programmes. 45 46 47 extensively drug-resistant TB (XDR-TB) has now been reported in 105 58 countries, and accounts for approximately 30,000 TB patients in 2016. If these 59 numbers are to reduce in line with milestones set by the WHO End TB Strategy, 60 alternative therapeutic agents that target novel pathways are urgently required. 61 62
Introduction 48
Tuberculosis (TB) remains a major global health issue, despite it being over 49 twenty years since the World Health Organisation (WHO) declared TB a global 50 emergency (1). In 2016, TB killed around 1.3 million people and now ranks 51 alongside HIV as the leading cause of death globally. It has been estimated 52 that almost 6.3 million new cases of TB are to have occurred in 2016; 46% of 53 these new TB cases were individuals co-infected with HIV. Alarmingly, an 54 To identify which of the 1200 FDA approved drugs in the Prestwick Chemical 83
Library ® inhibit the growth of mycobacteria, a high throughput fluorescence 84 screen was used to measure GFP expression in strains of both M. smegmatis 85 and M. bovis BCG (GFP microplate assay [GFPMA]) (6). M. 86 smegmatis_pSMT3_eGFP and M. bovis BCG_pSMT3_eGFP were cultured in 87 96-well plates in the presence of 20 µM compound from the Prestwick Chemical 88 Library ®. GFP fluorescence was measured at specified time points and data 89 was normalized against both positive and negative controls to produce a scatter 90 graph of the survival percentages (Fig. 1) . In order to assess the reproducibility 91 and robustness of the GFPMA HTS, we calculated Z` factor values for each of 92 the assay plates used to screen the 1200 compounds of the Prestwick 93
Chemical Library ® against both M. smegmatis_pSMT3_eGFP and M. bovis 94
BCG_pSMT3_eGFP. The Z' values of the primary screen against M. 95 smegmatis vary between 0.4 and 0.9 across each of the assay plates used in 96 the screen (Fig. S1 ). In case of the primary screen for M. bovis BCG, the Z` 97 values are consistent between 0.8 and 0.9 across all assay plates (Fig. S1 ). 98
However, since all assay plates used in the experiment derived Z' values ≥ 0.4, 99 all data generated was deemed suitable for further processing (7) . In order to 100 understand the variability in the data and significance of the hits identified from 101 the scatter plot ( Fig. 1) , we analysed the variance of data both between and 102
across replicate experiments carried out using M. smegmatis and M. bovis BCG. 103
The overall coefficient of correlation (r 2 ) values for replicate assays were 104 calculated to be 0.63 and to 0.89 for M. smegmatis_pSMT3_eGFP and M. bovis 105 BCG_pSMT3_eGFP, respectively (Fig. 2) . This indicates increased variance in 106 the data for assays conducted with M. smegmatis compared to screens 107 performed using M. bovis BCG. We analysed the frequency distribution of data 108 both within and across each primary screen using M. smegmatis and M. bovis 109 BCG (Fig. 3) . For M. smegmatis, we observed that 31.5 % of the compounds 110 screened in the library induced ≤ 75 % survival of bacterial cell growth in the 111 primary screen (Fig. 3) . For BCG, 21 % of the library induced ≤ 75 % survival 112 of bacterial cell growth in the primary screen ( Fig. 3 ). We applied a minimum 113 cut-off of ≤25 % bacterial cell survival at 20 µM compound, as a parameter that 114 defined an antimycobacterial hit that would be further investigated in 115 downstream experiments (Fig. 1 ). In this regard, we observed an almost 116 identical hit rate of 6.9% and 6.8% for compounds inducing ≤ 25 % survival for 117 M. smegmatis and BCG, respectively ( Fig. 3) . 118
119
The initial screen against M. smegmatis generated 83 hits which inhibited the 120 survival of this fast-growing species of mycobacterium below 25% (Fig. 1A) . 121
The screen against the slower growing mycobacterial strain M. bovis BCG 122 revealed 81 hits ( Fig. 1A ) which inhibited the growth of the bacteria below 25% 123 ( Fig. 1B) . Categorisation of these hits (<25% survival) into pharmacological 124 groups reveals that an almost equal number of fluoroquinolones, macrolides, 125 polyketide antibiotics, antimycobacterial drugs, and antiseptics display 126 inhibitory activity against both M. smegmatis and BCG whilst the 127 aminoglycosides displayed more inhibitory activity towards M. smegmatis 128 compared to BCG (Fig. 4 ). Other notable classes of drugs that inhibit the growth 129 of both M. smegmatis and BCG include the amphenicols, glycopeptides and 130 non-ribosomal peptide antibiotics, antihistamines, acetylcholine esterase 131 inhibitors, antiemetic, antimalarial, antiprotozoal and surfactants ( Fig. 4) . 132
Notable species-specific inhibitors affecting only M. smegmatis were also 133 identified belonging to antiestrogen, antiarrhythmic and antipsychotic drugs (Fig. 134 4) . For BCG, it appears that the cephalosporin antibiotics are only able to inhibit 135 the slower growing mycobacterial species and do not affect the faster growing 136 saprophytic organism M. smegmatis. Other significant drug classes that only 137 inhibit BCG include anticancer agents, antidiabetics, anticonvulsants and 138 angiotensin antagonists ( Fig. 4) . 139
140
All hits from the primary screen (displaying <25% survival) were filtered to 141 remove all known antimycobacterial drugs and a significant number of other 142 antimicrobial agents (5) . The remaining drugs were then clustered into one of 143 three groups based upon their inhibitory activity against either fast-growing (M. showing overlapping activity. Each cluster of drugs was further ranked and 146
given a priority score that was based on the apparent potency of the drug and 147 potential novelty of its mode of action from literature-based searches. 148 149 Secondary screening and hit confirmation against M. smegmatis 150
Minimal Inhibitory Concentrations (MIC) were determined using the 151 standardized broth dilution method and then subsequently measured on solid 152 medium in order to ascertain the concentration required to generate resistant 153 mutants ( Fig. S2 ). Among the drugs tested against M. smegmatis, the most 154 potent was meclocycline sulfosalicylate with a liquid and solid MIC of 0.10 µM 155 and 0.2 µM, respectively (Table 1) . Auranofin also displayed a relatively low 156 solid MIC of 6.0 µM although this was 22-fold higher than its liquid MIC values 157 (0.27 µM). Other drugs tested for MIC determination were alexidine and 158 chlorhexidine which both exhibited relatively low MIC values of 6.15µM and 159 1.98µM, both of which are used as antimicrobials in dentistry (8) alexidine dihydrochloride was discounted for further study due to its structural 172 and functional similarity to chlorhexidine. Further investigation of ebselen 173 ceased due to mode of action deconvolution that has been previously 174 determined elsewhere (12). Ebselen is an organoselenium compound 175 approved by the FDA with a well-known pharmacological profile and is currently 176 being investigated for clinical use in the treatment of bipolar disorders and 177 strokes. Previous studies have shown that ebselen displays antimycobacterial 178
properties and is also effective against multidrug resistant Staphylococcus 179 aureus (MRSA) (2) . In M. tuberculosis, ebselen acts by covalently binding to an 180 active site cysteine residue in antigen 85. Antigen 85 is a complex of secreted 181 proteins (Ag85A, Ag85B and Ag85C) which play an important role in the 182 synthesis of trehalose dimycolates (TDM) and mycolylarabinogalactan (mAG) 183 (12). 184 185
Secondary screening and hit confirmation against BCG 186
MIC studies of the compounds listed in Table 2 Table 2 ). Astemizole (used for general allergies, asthma and rhinitis), 205 tripelennamine (hay fever and rhinitis) and olopatadine (allergic conjunctivitis) 206 are mildly anti-cholinergic and act as H1 receptor antagonists (17) (18) (19) (20) . Of the 207 antidiabetic drugs displaying activity towards BCG, glipizide and rosiglitazone 208 have an MIC value of 191.1 µM and 43.15 µM, respectively ( Table 2) . Glipizide 209 is a second-generation sulfonylurea drug that is prescribed for hypoglycaemia 210 in type II diabetes and is known to act by stimulating insulin production and 211 correcting cellular lesions which occur during diabetes mellitus (21, 22) . 212
Rosiglitazone, on the other hand, functions by activating peroxisome 213 proliferator activated receptors in adipocytes and sensitising them to insulin (23). 214
Pinaverium, that inhibits L-type calcium channels arresting influx of the Ca 2+ 215 (24), had an MIC of 28.3µM. Two other drugs which displayed relatively high 216 MIC values were granisetron and phentermine (Table 2) . Granisetron, an 217 antiemetic drug which is an agonist to the 5-hydroxytryptamine-3 receptor, 218 stimulates the vagus nerve responsible for reflex motility response (25), had an 219 MIC value of 210.6µM. Phentermine, which has been prescribed as an appetite 220 suppressant to control obesity and acts as an agonist to the human TAAR1 221 (Trace Amine Associate Receptor 1) (26), displayed an MIC of 375.00 µM and 222 was not tested further due to the high concentrations required for inhibitory 223 activity. These drugs were then further tested to establish MICs on solid media 224 in order to determine accurate concentrations to generate spontaneous 225 resistant mutants for mode of action studies. We observed that, upon solid agar 226 MIC testing against BCG, the general trend was that the drugs displayed 5 to 227 100-fold higher MIC values when compared to MIC values obtained by broth 228 dilution method. For some of the drugs this was attributed to low solubility in 229 solid media as many precipitated during the cooling of the agar medium. 230
Glipizide, olopatadine and granisetron yielded solid MIC values greater than 231 0.5mM; these drugs precipitated out at higher concentrations and appeared to 232
show no noticeable inhibitory activity against BCG (Fig. S3 ). Rosiglitazone 233 displayed the highest MIC value at approximately 1.5 mM. Thonzonium and 234 florfenicol had a 5-fold increase in their solid MIC values but were still around 235 5µM and effectively inhibited the growth of BCG on solid agar ( Table 2) . 236
Pentamidine, astemizole and pinaverium had solid MIC values of around 0.05 237 mM while there was a 2-fold increase in the MIC value for tripelennamine 238 (compared to its liquid MIC) of 0.1 mM ( Table 2 ). All compounds listed in Table  239 1 and Table 2 were tested in an Alamar Blur ® assay against M. tuberculosis 240 (Supplementary Information) and the drugs that displayed any notable anti-TB 241 activity are listed in Table 3 . Both ebselen and auranofin displayed MICs of 242 18.51 µM and 0.27 µM, which are in close agreement with previously published 243 values (12, 27) . In addition, the estrogen receptor modulating drugs 244 clomiphene and raloxifene inhibited the growth of M. tuberculosis H37Rv with 245 MICs of 7.59 µM and 22.10 µM, respectively (we were unable to accurately 246 determine the MIC for Tamoxifen) (Table 3) . Finally, GBR12909, used in the 247 clinic to treat cocaine addiction) inhibited the growth of M. tuberculosis with an 248 MIC of 26.64 µM. It is interesting to note however, that all of the drugs listed in 249 Table 3 were identified as hits from screens conducted against M. smegmatis 250 and not M. bovis BCG (Table 1 and Table 2 ). 251 252 Generation of spontaneous resistant mutants to determine mode of 253
action. 254
We attempted to generate spontaneous resistant mutants in both M. smegmatis 255 and BCG against a selection of drugs identified in Table 1 and Table 2 , 256 respectively. However, we were only able to obtain drug-resistant isolates for 257 meclocyline sulfosalicylate, tamoxifen citrate and GBR12909 in M. smegmatis 258 (Table 4 ) and florfenicol, pentamidine and tripelennamine in BCG (Table 5) . 259
Analysis of the M. smegmatis meclocyline sulfosalicylate mutant revealed a 260 synonymous single nucleotide polymorphism (SNPs) mutation in the gene 261 MSMEG_3619 (Mtb ortholog Rv1856c), a probable oxidoreductase deemed 262 non-essential by the Himar-I based transposon mutagenesis 21 , but also 263
showing importance as having a growth advantage which results in an 264 improvement in fitness when disrupted (28). A single SNP (P122S) was also 265 observed in MSMEG_5249 (Mtb ortholog Rv1093) glyA1 which is a serine 266 hydroxymethyltransferase with possible roles of glycine to serine inter-267 conversion and the generation of 5, 10-methyenetetrahydrofolate which plays 268 an important role in providing precursors for cellular redox balancing, 269 methylation reactions and a role in thymidylate biosynthesis (Table 4) . GlyA1 is 270 also thought to be an essential gene (28, 29) and it has also been identified as 271 one of the proteins which undergoes PUPylation (Ubquitinylation by prokaryotic 272 ubiquitin protein) in mycobacteria (30). The M. smegmatis tamoxifen citrate 273 resistant mutant exhibited a frame shift mutation in the gene MSMEG_6431 274 (Mtb ortholog Rv3849) espR which encodes for a protein involved in 275 transcriptional regulation of the three genes Rv3136c-Rv3614c required for the 276 ESX-1 system (Table 4 ). EspR binds to the promotor region and regulates ESX-277 1, therefore controlling virulence of mycobacteria (31). Spontaneous resistant 278 mutants raised against GBR12909 in M. smegmatis produced consistent 279 multiple mutations in MSMEG_3033 (aroB) ( Table 4) . AroB is predicted to be 280 an essential gene as studied in M. tuberculosis (28, 29) and it encodes for 3-281 dehydroquinote synthase, which is one of several enzymes participating in the 282 shikimate biosynthetic pathway (32). AroB is a homomeric enzyme, is the 283 second enzyme in the shikimate biosynthetic pathway and is present in various 284 bacterial species such as Corynebacterium glutamicum, Escherichia coli, 285
Bacillus subtilis and other fungi, plant and apicomplexan parasites (33) (34) (35) . 286
AroB makes for an important target due to its essentiality in M. tuberculosis and 287 absence of this biochemical pathway in mammals (28, 29, 33) . Spontaneous 288 resistant mutants were generated for florfenicol in BCG, revealing a point 289 mutation in BCG_1533 (echA12) gene which encodes for a putative enoyl CoA 290 hydratase ( Table 5 ). EchA12 has been shown to be membrane localized within 291 the mycobacterial cell membrane (36), however the gene was not found to be 292 essential through Himar-I based transposon mutagenesis (28, 29) . It has been 293 suggested that EchA12 is involved in lipid membrane metabolism and is found 294 to co-localise with thioredoxine A (36) and CtpD, which is an ATPase involved 295 with the metalation of proteins secreted during redox stress (37). Three 296 additional point mutations were also observed in the florfenicol resistant mutant. 297
A single guanine to adenine point mutation in the gene BCG_3185 (PPE50) 298 which encodes for a protein belonging to the PPE family, generates a G251D 299 mutation. BCG_3508 (rpsI) encodes for a probable 30S ribosomal protein and 300 contains a P17A mutation in the florfenicol mutant ( Table 5 ). Florfenicol is a 301 fluorinated form of thiamphenicol which belongs to the amphenicol family of 302 antibiotics, whose mode of action is through binding to the 23S rRNA of the 50S 303 ribosomal unit (38). Finally, we also observed a V271A point mutation in 304
BCG_3755c, which encodes for a glycerol kinase (GlpK), which catalyses the 305 rate limiting step in glycerol metabolism of converting glycerol to glycerol-3-306 phosphate (39, 40) . Mutations in glpK, have previously been observed when 307 generating resistant mutants to drugs in an attempt to deconvolute their mode 308 of action (41, 42) . In our investigation of pentamidine activity, we identified an 309 identical mutation in glpK, two separate non-synonymous SNPs in BCG_0763, 310 which encodes for putative membrane protein with a domain of unknown 311 function, and a single SNP in BCG_1609, which encodes for mmpl6 ( Table 5) . 312
Mycobacterial membrane protein large (MmpL) are membrane proteins 313 involved in shuttling lipid components across the plasma membrane and have 314 been known to play an important role in drug resistance mechanisms, 315 membrane physiology and virulence of the bacterium (43). The tripelennamine 316 mutant had a single point mutation in the promoter region of BCG_3090, a 317 multi-drug transport integral membrane protein (mmr) ( Table 5) , which is a 318 known efflux pump involved in drug resistance with high susceptibility to 319 quaternary compounds (44). This suggest that exposure to tripelennamine 320 might induce a mutation that causes increased overexpression of Mmr which 321 could alter the ability of the bacterium to efflux drugs. Chemical Library ® that inhibit the growth of mycobacteria have an average 362 clogP value of 5.7 (48). Hydrophobic drugs have a tendency to enter into the 363 lipid layers of the mycobacterial cell envelope and then move laterally through 364 the membrane due to their inability to cross the plasma membrane into the 365 cytoplasm. While traversing the bilayer, these hydrophobic compounds 366 interact with membrane proteins and thus there is an increased probability of 367 the drugs inhibiting such targets thereby producing membrane protein related 368 mutations in spontaneously generated mutants during mode of action studies 369 (48). Alexidine dihydrochloride and thonzonium bromide were amongst the hits 370 observed in this study that have uncoupling properties and might generated a 371 membrane protein mutation (13). In this study, screening the Prestwick 372
Chemical Library ® also identified inhibitors such as calcium channel blockers, 373 antihistamines, antifungal azoles and, unsurprisingly, a variety of antinfectives 374 ( Fig. 4) . Calcium channel inhibitors are generally small hydrophobic molecules 375 which have the ability to enter the phospholipid bilayer and can diffuse through 376 the membrane inhibiting metabolic functions due to interactions with proteins 377 and boundary lipids (50). Antifungal azoles, which have been shown to elicit 378 inhibitory activity against mycobacteria, act by targeting the CYP121 and 379 CYP130 cytochrome P450 systems (51) . Our screening of the Prestwick 380 Each assay plate was checked for robustness and reproducibility by calculating 436 the Z'-factor using the following equation; 437
For the primary screen, positive controls and negative controls were included 439 in columns 1 and 2 respectively. The Z' was found to be on average 0.75, well 440 above the Z'>0.5 which is widely regarded as being suitable for HTS. All 1200 441 drugs from the Prestwick Chemical Library ® were screened in duplicate and 442 hits were identified as inhibiting cell growth by ≥75%, as determined by 443 measuring eGFP fluorescence. 444 445
Validation of selected hits and MIC determination in liquid media 446
Drugs selected for further study were purchased from a variety of commercial 447 vendors. Drugs were dissolved into 100% DMSO resulting in a 10 mM stock 448 that was subsequently used to generate a 10-point 3-fold serial dilution which 449 provided a dose response curve with maximum and minimum drug 450 concentration of 500 µM and 0.0254nM, respectively. Data was normalised as 451 described above. The concentration of drug that is required to inhibit cell growth 452 
